Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agents Therapy from the ACTG A5336 Study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1930
Abstract: Ruxolitinib is an FDA-approved orally administered Janus kinase (JAK 1/2) inhibitor that reduces cytokine-induced inflammation. As part of a randomized, Phase 2, open label trial, ruxolitinib (10 mg, bid) was administered to HIV+ , virologically… read more here.
Keywords: pharmacokinetics ruxolitinib; antiretroviral agents; study; ruxolitinib hiv ... See more keywords
Deep Phenotypic Analysis of Blood and Lymphoid T and NK Cells From HIV+ Controllers and ART-Suppressed Individuals
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.803417
Abstract: T and natural killer (NK) cells are effector cells with key roles in anti-HIV immunity, including in lymphoid tissues, the major site of HIV persistence. However, little is known about the features of these effector… read more here.
Keywords: controllers art; suppressed individuals; phenotypic; art suppressed ... See more keywords